New Delhi, January 07, 2019: Eisai Co., Ltd. has launched the in-house discovered and developed antiepileptic drug (AED) Fycompa, (generic…
Tokyo, July 17, 2019: Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate)…
A Focused Drug Discovery Approach That Integrates Human Genetics/ Data Science/ Precision Chemistry Tokyo, July 10, 2019: Eisai Co., Ltd.…
Tokyo, May 21, 2019: Eisai Co., Ltd. announced today that Eisai has received approval from "Science Based Targets (SBT) Initiative"…
As Monotherapy for Partial-Onset Seizures, Pediatric Indication for Partial-Onset Seizures, as Well as New Formulation Tokyo, February 03, 2019: Eisai Co., Ltd.…
Tokyo, Septembe 02, 2018: Eisai Co., Ltd. announced that its South Korea subsidiary Eisai Korea Inc. received approval for the…